Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 249 entries
Sorted by: Best Match Show Resources per page
Association between malaria exposure and Kaposi's sarcoma-associated herpes virus seropositivity in Uganda.

Tropical medicine & international health : TM & IH

Nalwoga A, Cose S, Wakeham K, Miley W, Ndibazza J, Drakeley C, Elliott A, Whitby D, Newton R.
PMID: 25611008
Trop Med Int Health. 2015 May;20(5):665-672. doi: 10.1111/tmi.12464. Epub 2015 Feb 09.

OBJECTIVE: Unlike other herpes viruses, Kaposi's sarcoma-associated herpes virus (KSHV) is not ubiquitous worldwide and is most prevalent in sub-Saharan Africa. The reasons for this are unclear. As part of a wider investigation of factors that facilitate transmission in...

Cite
Nalwoga A, Cose S, Wakeham K, et al. Association between malaria exposure and Kaposi's sarcoma-associated herpes virus seropositivity in Uganda. Trop Med Int Health. 2015;20(5):665-672doi: 10.1111/tmi.12464.
Nalwoga, A., Cose, S., Wakeham, K., Miley, W., Ndibazza, J., Drakeley, C., Elliott, A., Whitby, D., & Newton, R. (2015). Association between malaria exposure and Kaposi's sarcoma-associated herpes virus seropositivity in Uganda. Tropical medicine & international health : TM & IH, 20(5), 665-672. https://doi.org/10.1111/tmi.12464
Nalwoga, Angela, et al. "Association between malaria exposure and Kaposi's sarcoma-associated herpes virus seropositivity in Uganda." Tropical medicine & international health : TM & IH vol. 20,5 (2015): 665-672. doi: https://doi.org/10.1111/tmi.12464
Nalwoga A, Cose S, Wakeham K, Miley W, Ndibazza J, Drakeley C, Elliott A, Whitby D, Newton R. Association between malaria exposure and Kaposi's sarcoma-associated herpes virus seropositivity in Uganda. Trop Med Int Health. 2015 May;20(5):665-672. doi: 10.1111/tmi.12464. Epub 2015 Feb 09. PMID: 25611008; PMCID: PMC4390463.
Copy Download .nbib Format: NLM
Evolutionary medicine: A meaningful connection between omics, disease, and treatment.

Proteomics. Clinical applications

Abu-Asab M, Chaouchi M, Amri H.
PMID: 18458745
Proteomics Clin Appl. 2008 Feb;2(2):122-134. doi: 10.1002/prca.200780047.

The evolutionary nature of diseases requires that their omics be analyzed by evolution-compatible analytical tools such as parsimony phylogenetics in order to reveal common mutations and pathways' modifications. Since the heterogeneity of the omics data renders some analytical tools...

Cite
Abu-Asab M, Chaouchi M, Amri H. Evolutionary medicine: A meaningful connection between omics, disease, and treatment. Proteomics Clin Appl. 2008;2(2):122-134doi: 10.1002/prca.200780047.
Abu-Asab, M., Chaouchi, M., & Amri, H. (2008). Evolutionary medicine: A meaningful connection between omics, disease, and treatment. Proteomics. Clinical applications, 2(2), 122-134. https://doi.org/10.1002/prca.200780047
Abu-Asab, Mones, et al. "Evolutionary medicine: A meaningful connection between omics, disease, and treatment." Proteomics. Clinical applications vol. 2,2 (2008): 122-134. doi: https://doi.org/10.1002/prca.200780047
Abu-Asab M, Chaouchi M, Amri H. Evolutionary medicine: A meaningful connection between omics, disease, and treatment. Proteomics Clin Appl. 2008 Feb;2(2):122-134. doi: 10.1002/prca.200780047. PMID: 18458745; PMCID: PMC2367146.
Copy Download .nbib Format: NLM
A general framework for the evaluation of clinical trial quality.

Reviews on recent clinical trials

Berger VW, Alperson SY.
PMID: 19463104
Rev Recent Clin Trials. 2009 May;4(2):79-88. doi: 10.2174/157488709788186021.

Flawed evaluation of clinical trial quality allows flawed trials to thrive (get funded, obtain IRB approval, get published, serve as the basis of regulatory approval, and set policy). A reasonable evaluation of clinical trial quality must recognize that any...

Cite
Berger VW, Alperson SY. A general framework for the evaluation of clinical trial quality. Rev Recent Clin Trials. 2009;4(2):79-88doi: 10.2174/157488709788186021.
Berger, V. W., & Alperson, S. Y. (2009). A general framework for the evaluation of clinical trial quality. Reviews on recent clinical trials, 4(2), 79-88. https://doi.org/10.2174/157488709788186021
Berger, Vance W, and Alperson, Sunny Y. "A general framework for the evaluation of clinical trial quality." Reviews on recent clinical trials vol. 4,2 (2009): 79-88. doi: https://doi.org/10.2174/157488709788186021
Berger VW, Alperson SY. A general framework for the evaluation of clinical trial quality. Rev Recent Clin Trials. 2009 May;4(2):79-88. doi: 10.2174/157488709788186021. PMID: 19463104; PMCID: PMC2694951.
Copy Download .nbib Format: NLM
Resistance to integrase inhibitors.

Viruses

Métifiot M, Marchand C, Maddali K, Pommier Y.
PMID: 20706558
Viruses. 2010 Jun 25;2(7):1347-66. doi: 10.3390/v2071347.

Integrase (IN) is a clinically validated target for the treatment of human immunodeficiency virus infections and raltegravir exhibits remarkable clinical activity. The next most advanced IN inhibitor is elvitegravir. However, mutant viruses lead to treatment failure and mutations within...

Cite
Métifiot M, Marchand C, Maddali K, et al. Resistance to integrase inhibitors. Viruses. 2010;2(7):1347-66doi: 10.3390/v2071347.
Métifiot, M., Marchand, C., Maddali, K., & Pommier, Y. (2010). Resistance to integrase inhibitors. Viruses, 2(7), 1347-66. https://doi.org/10.3390/v2071347
Métifiot, Mathieu, et al. "Resistance to integrase inhibitors." Viruses vol. 2,7 (2010): 1347-66. doi: https://doi.org/10.3390/v2071347
Métifiot M, Marchand C, Maddali K, Pommier Y. Resistance to integrase inhibitors. Viruses. 2010 Jun 25;2(7):1347-66. doi: 10.3390/v2071347. PMID: 20706558; PMCID: PMC2920056.
Copy Download .nbib Format: NLM
An Efficient Stochastic Search for Bayesian Variable Selection with High-Dimensional Correlated Predictors.

Computational statistics & data analysis

Kwon D, Landi MT, Vannucci M, Issaq HJ, Prieto D, Pfeiffer RM.
PMID: 21686315
Comput Stat Data Anal. 2011 Oct 01;55(10):2807-2818. doi: 10.1016/j.csda.2011.04.019.

We present a Bayesian variable selection method for the setting in which the number of independent variables or predictors in a particular dataset is much larger than the available sample size. While most existing methods allow some degree of...

Cite
Kwon D, Landi MT, Vannucci M, et al. An Efficient Stochastic Search for Bayesian Variable Selection with High-Dimensional Correlated Predictors. Comput Stat Data Anal. 2011;55(10):2807-2818doi: 10.1016/j.csda.2011.04.019.
Kwon, D., Landi, M. T., Vannucci, M., Issaq, H. J., Prieto, D., & Pfeiffer, R. M. (2011). An Efficient Stochastic Search for Bayesian Variable Selection with High-Dimensional Correlated Predictors. Computational statistics & data analysis, 55(10), 2807-2818. https://doi.org/10.1016/j.csda.2011.04.019
Kwon, Deukwoo, et al. "An Efficient Stochastic Search for Bayesian Variable Selection with High-Dimensional Correlated Predictors." Computational statistics & data analysis vol. 55,10 (2011): 2807-2818. doi: https://doi.org/10.1016/j.csda.2011.04.019
Kwon D, Landi MT, Vannucci M, Issaq HJ, Prieto D, Pfeiffer RM. An Efficient Stochastic Search for Bayesian Variable Selection with High-Dimensional Correlated Predictors. Comput Stat Data Anal. 2011 Oct 01;55(10):2807-2818. doi: 10.1016/j.csda.2011.04.019. PMID: 21686315; PMCID: PMC3113479.
Copy Download .nbib Format: NLM
Clinical trial designs for evaluating the medical utility of prognostic and predictive biomarkers in oncology.

Personalized medicine

Simon R.
PMID: 20383292
Per Med. 2010 Jan 01;7(1):33-47. doi: 10.2217/pme.09.49.

Physicians need improved tools for selecting treatments for individual patients. Many diagnostic entities hat were traditionally viewed as individual diseases are heterogeneous in their molecular pathogenesis and treatment responsiveness. This results in the treatment of many patients with ineffective...

Cite
Simon R. Clinical trial designs for evaluating the medical utility of prognostic and predictive biomarkers in oncology. Per Med. 2010;7(1):33-47doi: 10.2217/pme.09.49.
Simon, R. (2010). Clinical trial designs for evaluating the medical utility of prognostic and predictive biomarkers in oncology. Personalized medicine, 7(1), 33-47. https://doi.org/10.2217/pme.09.49
Simon, Richard. "Clinical trial designs for evaluating the medical utility of prognostic and predictive biomarkers in oncology." Personalized medicine vol. 7,1 (2010): 33-47. doi: https://doi.org/10.2217/pme.09.49
Simon R. Clinical trial designs for evaluating the medical utility of prognostic and predictive biomarkers in oncology. Per Med. 2010 Jan 01;7(1):33-47. doi: 10.2217/pme.09.49. PMID: 20383292; PMCID: PMC2851173.
Copy Download .nbib Format: NLM
Synthesis of a Homologous Series of Side Chain Extended Orthogonally-Protected Aminooxy-Containing Amino Acids.

Synthesis

Liu F, Thomas J, Burke TR.
PMID: 19122755
Synthesis (Stuttg). 2008;15:2432-2438. doi: 10.1055/s-2008-1078600.

Practical methodology is reported for the synthesis of a homologous series of side chain extended amino acids containing aminooxy functionality bearing orthogonal protection suitable for Fmoc peptide synthesis. These reagents may be useful for the preparation of libraries containing...

Cite
Liu F, Thomas J, Burke TR. Synthesis of a Homologous Series of Side Chain Extended Orthogonally-Protected Aminooxy-Containing Amino Acids. Synthesis (Stuttg). 2008;15:2432-2438doi: 10.1055/s-2008-1078600.
Liu, F., Thomas, J., & Burke, T. R. (2008). Synthesis of a Homologous Series of Side Chain Extended Orthogonally-Protected Aminooxy-Containing Amino Acids. Synthesis, 152432-2438. https://doi.org/10.1055/s-2008-1078600
Liu, Fa, et al. "Synthesis of a Homologous Series of Side Chain Extended Orthogonally-Protected Aminooxy-Containing Amino Acids." Synthesis vol. 15 (2008): 2432-2438. doi: https://doi.org/10.1055/s-2008-1078600
Liu F, Thomas J, Burke TR. Synthesis of a Homologous Series of Side Chain Extended Orthogonally-Protected Aminooxy-Containing Amino Acids. Synthesis (Stuttg). 2008;15:2432-2438. doi: 10.1055/s-2008-1078600. PMID: 19122755; PMCID: PMC2491720.
Copy Download .nbib Format: NLM
The evolving role of nuclear molecular imaging in cancer.

Expert opinion on medical diagnostics

Kurdziel K, Ravizzini G, Croft B, Tatum J, Choyke P, Kobayashi H.
PMID: 19122861
Expert Opin Med Diagn. 2008 Jul;2(7):829-842. doi: 10.1517/17530059.2.7.829.

BACKGROUND: Novel therapies targeted to specific tumor pathways are entering the clinic. The need for in vivo monitoring of resulting molecular changes, particularly with respect to the tumor microenvironment, is growing. Molecular imaging is evolving to include a variety...

Cite
Kurdziel K, Ravizzini G, Croft B, et al. The evolving role of nuclear molecular imaging in cancer. Expert Opin Med Diagn. 2008;2(7):829-842doi: 10.1517/17530059.2.7.829.
Kurdziel, K., Ravizzini, G., Croft, B., Tatum, J., Choyke, P., & Kobayashi, H. (2008). The evolving role of nuclear molecular imaging in cancer. Expert opinion on medical diagnostics, 2(7), 829-842. https://doi.org/10.1517/17530059.2.7.829
Kurdziel, Ka, et al. "The evolving role of nuclear molecular imaging in cancer." Expert opinion on medical diagnostics vol. 2,7 (2008): 829-842. doi: https://doi.org/10.1517/17530059.2.7.829
Kurdziel K, Ravizzini G, Croft B, Tatum J, Choyke P, Kobayashi H. The evolving role of nuclear molecular imaging in cancer. Expert Opin Med Diagn. 2008 Jul;2(7):829-842. doi: 10.1517/17530059.2.7.829. PMID: 19122861; PMCID: PMC2600859.
Copy Download .nbib Format: NLM
MicroRNA polymorphisms: a giant leap towards personalized medicine.

Personalized medicine

Mishra PJ.
PMID: 20428464
Per Med. 2009 Mar 01;6(2):119-125. doi: 10.2217/17410541.6.2.119.

"An individual's genetic inheritance of microRNA polymorphisms associated with disease progression, prognosis and treatment holds the key to create safer and more personalized drugs and can be a giant leap towards personalized medicine."

Cite
Mishra PJ. MicroRNA polymorphisms: a giant leap towards personalized medicine. Per Med. 2009;6(2):119-125doi: 10.2217/17410541.6.2.119.
Mishra, P. J. (2009). MicroRNA polymorphisms: a giant leap towards personalized medicine. Personalized medicine, 6(2), 119-125. https://doi.org/10.2217/17410541.6.2.119
Mishra, Prasun J. "MicroRNA polymorphisms: a giant leap towards personalized medicine." Personalized medicine vol. 6,2 (2009): 119-125. doi: https://doi.org/10.2217/17410541.6.2.119
Mishra PJ. MicroRNA polymorphisms: a giant leap towards personalized medicine. Per Med. 2009 Mar 01;6(2):119-125. doi: 10.2217/17410541.6.2.119. PMID: 20428464; PMCID: PMC2860186.
Copy Download .nbib Format: NLM
A network of its own: the unique interactome of the Hsp90 cochaperone, Sba1/p23.

Molecular cell

Prince T, Neckers L.
PMID: 21777805
Mol Cell. 2011 Jul 22;43(2):159-60. doi: 10.1016/j.molcel.2011.07.005.

In this issue of Molecular Cell, Echtenkamp et al. (2011) show that the molecular chaperone Sba1/p23, thought to function primarily as a key modulator of the Hsp90 chaperone complex, also operates in its own sphere of influence outside of...

Cite
Prince T, Neckers L. A network of its own: the unique interactome of the Hsp90 cochaperone, Sba1/p23. Mol Cell. 2011;43(2):159-60doi: 10.1016/j.molcel.2011.07.005.
Prince, T., & Neckers, L. (2011). A network of its own: the unique interactome of the Hsp90 cochaperone, Sba1/p23. Molecular cell, 43(2), 159-60. https://doi.org/10.1016/j.molcel.2011.07.005
Prince, Thomas, and Neckers, Len. "A network of its own: the unique interactome of the Hsp90 cochaperone, Sba1/p23." Molecular cell vol. 43,2 (2011): 159-60. doi: https://doi.org/10.1016/j.molcel.2011.07.005
Prince T, Neckers L. A network of its own: the unique interactome of the Hsp90 cochaperone, Sba1/p23. Mol Cell. 2011 Jul 22;43(2):159-60. doi: 10.1016/j.molcel.2011.07.005. PMID: 21777805; PMCID: PMC3148939.
Copy Download .nbib Format: NLM
Current priorities for public health practice in addressing the role of human genomics in improving population health.

American journal of preventive medicine

Khoury MJ, Bowen MS, Burke W, Coates RJ, Dowling NF, Evans JP, Reyes M, St Pierre J.
PMID: 21406285
Am J Prev Med. 2011 Apr;40(4):486-93. doi: 10.1016/j.amepre.2010.12.009.

In spite of accelerating human genome discoveries in a wide variety of diseases of public health significance, the promise of personalized health care and disease prevention based on genomics has lagged behind. In a time of limited resources, public...

Cite
Khoury MJ, Bowen MS, Burke W, et al. Current priorities for public health practice in addressing the role of human genomics in improving population health. Am J Prev Med. 2011;40(4):486-93doi: 10.1016/j.amepre.2010.12.009.
Khoury, M. J., Bowen, M. S., Burke, W., Coates, R. J., Dowling, N. F., Evans, J. P., Reyes, M., & St Pierre, J. (2011). Current priorities for public health practice in addressing the role of human genomics in improving population health. American journal of preventive medicine, 40(4), 486-93. https://doi.org/10.1016/j.amepre.2010.12.009
Khoury, Muin J, et al. "Current priorities for public health practice in addressing the role of human genomics in improving population health." American journal of preventive medicine vol. 40,4 (2011): 486-93. doi: https://doi.org/10.1016/j.amepre.2010.12.009
Khoury MJ, Bowen MS, Burke W, Coates RJ, Dowling NF, Evans JP, Reyes M, St Pierre J. Current priorities for public health practice in addressing the role of human genomics in improving population health. Am J Prev Med. 2011 Apr;40(4):486-93. doi: 10.1016/j.amepre.2010.12.009. PMID: 21406285; PMCID: PMC5624316.
Copy Download .nbib Format: NLM
Global Governmental Investment in Nanotechnologies.

Current nanoscience

Jia L.
PMID: 19865495
Curr Nanosci. 2005 Nov 01;1(3):263-266. doi: 10.2174/157341305774642957.

Nanotechnologies seem to have huge potential to bring benefits in areas as diverse as drug development, water decontamination, information and communication infrastructures, and the production of stronger, lighter and perfect nanomaterials. This potential attracts global investment from governments and...

Cite
Jia L. Global Governmental Investment in Nanotechnologies. Curr Nanosci. 2005;1(3):263-266doi: 10.2174/157341305774642957.
Jia, L. (2005). Global Governmental Investment in Nanotechnologies. Current nanoscience, 1(3), 263-266. https://doi.org/10.2174/157341305774642957
Jia, Lee. "Global Governmental Investment in Nanotechnologies." Current nanoscience vol. 1,3 (2005): 263-266. doi: https://doi.org/10.2174/157341305774642957
Jia L. Global Governmental Investment in Nanotechnologies. Curr Nanosci. 2005 Nov 01;1(3):263-266. doi: 10.2174/157341305774642957. PMID: 19865495; PMCID: PMC2768287.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 249 entries